- Home
- BTAI vs VRCA Comparison
BTAI vs VRCA Comparison
Compare BTAI & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- VRCA
- Stock Information
- Founded
- BTAI 2017
- VRCA 2013
- Country
- BTAI United States
- VRCA United States
- Employees
- BTAI N/A
- VRCA N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- BTAI Health Care
- VRCA Health Care
- Exchange
- BTAI Nasdaq
- VRCA Nasdaq
- Market Cap
- BTAI 52.7M
- VRCA 58.7M
- IPO Year
- BTAI 2018
- VRCA 2018
- Fundamental
- Price
- BTAI $3.01
- VRCA $4.12
- Analyst Decision
- BTAI Buy
- VRCA Hold
- Analyst Count
- BTAI 5
- VRCA 5
- Target Price
- BTAI $32.80
- VRCA $60.00
- AVG Volume (30 Days)
- BTAI 5.2M
- VRCA 43.5K
- Earning Date
- BTAI 11-13-2025
- VRCA 11-03-2025
- Dividend Yield
- BTAI N/A
- VRCA N/A
- EPS Growth
- BTAI N/A
- VRCA N/A
- EPS
- BTAI N/A
- VRCA N/A
- Revenue
- BTAI $868,000.00
- VRCA $14,704,000.00
- Revenue This Year
- BTAI N/A
- VRCA $332.45
- Revenue Next Year
- BTAI $614.78
- VRCA $12.85
- P/E Ratio
- BTAI N/A
- VRCA N/A
- Revenue Growth
- BTAI N/A
- VRCA 5.72
- 52 Week Low
- BTAI $1.17
- VRCA $3.82
- 52 Week High
- BTAI $13.28
- VRCA $20.01
- Technical
- Relative Strength Index (RSI)
- BTAI 41.66
- VRCA 27.18
- Support Level
- BTAI $2.86
- VRCA $4.35
- Resistance Level
- BTAI $3.95
- VRCA $5.23
- Average True Range (ATR)
- BTAI 0.34
- VRCA 0.37
- MACD
- BTAI -0.17
- VRCA -0.07
- Stochastic Oscillator
- BTAI 11.89
- VRCA 4.54
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.